Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study.
atherosclerotic cardiovascular disease
mortality
risk stratification
triglycerides
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
19 10 2021
19 10 2021
Historique:
pubmed:
9
10
2021
medline:
21
12
2021
entrez:
8
10
2021
Statut:
ppublish
Résumé
Background Patients with risk factors or established atherosclerotic cardiovascular disease remain at high-risk for ischemic events. Triglyceride levels may play a causal role. Methods and Results We performed a retrospective study of adults aged ≥45 years receiving statin therapy, with a low-density lipoprotein cholesterol of 41 to 100 mg/dL, and ≥1 risk factor or established atherosclerotic cardiovascular disease between 2010 and 2017. Outcomes included death, all-cause hospitalization, and major adverse cardiovascular events (myocardial infarction, stroke, or peripheral artery disease). The study sample included 373 389 primary prevention patients and 97 832 secondary prevention patients. The primary prevention cohort had a mean age of 65±10 years, with 51% women and 44% people of color, whereas the secondary prevention cohort had a mean age of 71±11 years, with 37% women and 32% people of color. Median triglyceride levels for the primary and secondary prevention cohorts were 122 mg/dL (interquartile range, 88-172 mg/dL) and 116 mg/dL (interquartile range, 84-164 mg/dL), respectively. In multivariable analyses, primary prevention patients with triglyceride levels ≥150 mg/dL were at lower adjusted risk of death (hazard ratio [HR], 0.91; 95% CI, 0.89-0.94) and higher risk of major adverse cardiovascular events (HR, 1.14; 95% CI, 1.05-1.24). In the secondary prevention cohort, patients with triglyceride levels ≥150 mg/dL were at lower adjusted risk of death (HR, 0.95; 95% CI, 0.92-0.97) and higher risk of all-cause hospitalization (HR, 1.03; 95% CI, 1.01-1.05) and major adverse cardiovascular events (HR, 1.04; 95% CI, 1.05-1.24). Conclusions In a contemporary cohort receiving statin therapy, elevated triglyceride levels were associated with a greater risk of atherosclerotic cardiovascular disease events and lower risk of death.
Identifiants
pubmed: 34622663
doi: 10.1161/JAHA.120.020377
pmc: PMC8751901
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Triglycerides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e020377Références
JAMA. 2006 Nov 1;296(17):2105-11
pubmed: 17077375
Lancet. 2007 Dec 1;370(9602):1829-39
pubmed: 18061058
Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):333-42
pubmed: 23685625
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
J Am Coll Cardiol. 2019 Aug 27;74(8):1159-1161
pubmed: 31439224
Perm J. 2012 Summer;16(3):37-41
pubmed: 23012597
Circulation. 2014 Feb 4;129(5):570-9
pubmed: 24192801
Circulation. 2006 Jun 13;113(23):2713-23
pubmed: 16754803
J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802
pubmed: 30898607
N Engl J Med. 2012 Jul 26;367(4):309-18
pubmed: 22686415
J Clin Lipidol. 2020 Jul - Aug;14(4):438-447.e3
pubmed: 32571728
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
J Am Coll Cardiol. 2019 Mar 26;73(11):1362-1364
pubmed: 30819552
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
Circ Cardiovasc Qual Outcomes. 2008 Nov;1(2):138-47
pubmed: 20031802
JAMA Cardiol. 2018 Mar 1;3(3):225-234
pubmed: 29387889
Am J Med. 2014 Dec;127(12):1186-94.e1
pubmed: 25195188
N Engl J Med. 2006 Mar 23;354(12):1264-72
pubmed: 16554528
Clin Cardiol. 2017 Mar;40(3):138-148
pubmed: 28294373
Am J Public Health. 1992 May;82(5):703-10
pubmed: 1566949
N Engl J Med. 2010 Apr 29;362(17):1563-74
pubmed: 20228404
JAMA. 2003 Nov 26;290(20):2685-92
pubmed: 14645310
N Engl J Med. 2011 Dec 15;365(24):2255-67
pubmed: 22085343
N Engl J Med. 2018 Oct 18;379(16):1540-1550
pubmed: 30146932
J Am Coll Cardiol. 2016 May 10;67(18):2118-2130
pubmed: 27151343
Cardiol Ther. 2020 Jun;9(1):207-213
pubmed: 32328971
JAMA. 2016 Sep 27;316(12):1289-97
pubmed: 27673306
Am J Med. 2015 Nov;128(11):1252.e1-1252.e11
pubmed: 26169887
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
N Engl J Med. 2010 Jun 10;362(23):2155-65
pubmed: 20558366
J Clin Endocrinol Metab. 2018 Aug 1;103(8):3019-3027
pubmed: 29850861
Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1043-5
pubmed: 18793105
Circulation. 2011 May 24;123(20):2292-333
pubmed: 21502576
Metab Syndr Relat Disord. 2011 Feb;9(1):35-40
pubmed: 20958206
Metab Syndr Relat Disord. 2012 Apr;10(2):77-82
pubmed: 22224930
JAMA. 2010 Sep 22;304(12):1350-7
pubmed: 20805624
J Am Coll Cardiol. 2014 Dec 16;64(23):2525-40
pubmed: 25500239
Circulation. 2020 Feb 4;141(5):367-375
pubmed: 31707829
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209
pubmed: 30423391